Cargando…

Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy

Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yazhe, Malik, Shipra, Suh, Hee-Won, Xiao, Yong, Deng, Yanxiang, Fan, Rong, Huttner, Anita, Bindra, Ranjit S., Singh, Vijender, Saltzman, W. Mark, Bahal, Raman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908025/
https://www.ncbi.nlm.nih.gov/pubmed/36753549
http://dx.doi.org/10.1126/sciadv.abq7459
_version_ 1784884298092904448
author Wang, Yazhe
Malik, Shipra
Suh, Hee-Won
Xiao, Yong
Deng, Yanxiang
Fan, Rong
Huttner, Anita
Bindra, Ranjit S.
Singh, Vijender
Saltzman, W. Mark
Bahal, Raman
author_facet Wang, Yazhe
Malik, Shipra
Suh, Hee-Won
Xiao, Yong
Deng, Yanxiang
Fan, Rong
Huttner, Anita
Bindra, Ranjit S.
Singh, Vijender
Saltzman, W. Mark
Bahal, Raman
author_sort Wang, Yazhe
collection PubMed
description Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the seed region of oncomiRs 10b and 21. We entrapped these anti-miR sγPNAs in nanoparticles (NPs) formed from a block copolymer of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG). The surface of the NPs was functionalized with aldehydes to produce bioadhesive NPs (BNPs) with superior transfection efficiency and tropism for tumor cells. When combined with temozolomide, sγPNA BNPs administered via convection-enhanced delivery (CED) markedly increased the survival (>120 days) of two orthotopic (intracranial) mouse models of GBM. Hence, we established that BNPs loaded with anti-seed sγPNAs targeting multiple oncomiRs are a promising approach to improve the treatment of GBM, with a potential to personalize treatment based on tumor-specific oncomiRs.
format Online
Article
Text
id pubmed-9908025
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-99080252023-02-09 Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy Wang, Yazhe Malik, Shipra Suh, Hee-Won Xiao, Yong Deng, Yanxiang Fan, Rong Huttner, Anita Bindra, Ranjit S. Singh, Vijender Saltzman, W. Mark Bahal, Raman Sci Adv Biomedicine and Life Sciences Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the seed region of oncomiRs 10b and 21. We entrapped these anti-miR sγPNAs in nanoparticles (NPs) formed from a block copolymer of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG). The surface of the NPs was functionalized with aldehydes to produce bioadhesive NPs (BNPs) with superior transfection efficiency and tropism for tumor cells. When combined with temozolomide, sγPNA BNPs administered via convection-enhanced delivery (CED) markedly increased the survival (>120 days) of two orthotopic (intracranial) mouse models of GBM. Hence, we established that BNPs loaded with anti-seed sγPNAs targeting multiple oncomiRs are a promising approach to improve the treatment of GBM, with a potential to personalize treatment based on tumor-specific oncomiRs. American Association for the Advancement of Science 2023-02-08 /pmc/articles/PMC9908025/ /pubmed/36753549 http://dx.doi.org/10.1126/sciadv.abq7459 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Wang, Yazhe
Malik, Shipra
Suh, Hee-Won
Xiao, Yong
Deng, Yanxiang
Fan, Rong
Huttner, Anita
Bindra, Ranjit S.
Singh, Vijender
Saltzman, W. Mark
Bahal, Raman
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
title Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
title_full Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
title_fullStr Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
title_full_unstemmed Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
title_short Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy
title_sort anti-seed pnas targeting multiple oncomirs for brain tumor therapy
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908025/
https://www.ncbi.nlm.nih.gov/pubmed/36753549
http://dx.doi.org/10.1126/sciadv.abq7459
work_keys_str_mv AT wangyazhe antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT malikshipra antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT suhheewon antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT xiaoyong antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT dengyanxiang antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT fanrong antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT huttneranita antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT bindraranjits antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT singhvijender antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT saltzmanwmark antiseedpnastargetingmultipleoncomirsforbraintumortherapy
AT bahalraman antiseedpnastargetingmultipleoncomirsforbraintumortherapy